ChristopherClaytonPorterMD

PubMed

• Multicolor Light-Induced Immune Activation via Polymer Photocaged Cytokines.
  Lacey A Birnbaum, Emily C Sullivan, Priscilla Do, Biaggio Uricoli, Sunil S Raikar, Christopher C Porter, Curtis J Henry, Erik C Dreaden> ;Biomacromolecules. 2023 Mar 13
• 1 citations
  Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition.
  Suzanne P MacFarland, Luke Maese, Surya P Rednam, Junne Kamihara, Melissa R Perrino, Kim E Nichols, Garrett M Brodeur, Joshua D Schiffman, Sharon E Plon, Lisa R Diller...> ;Cancer Prevention Research. 2022 Oct 4
• 3 citations
  Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care.
  Ryan J Summers, Sharon M Castellino, Christopher C Porter, Tobey J MacDonald, Gargi D Basu, Szabolcs Szelinger, Manoj K Bhasin, Thomas Cash, Alexis B Carter, Robert Cr...> ;JCO Precision Oncology. 2022 Apr 1
• 7 citations
  Thrombopoietin-based CAR-T cells demonstrate in vitro and in vivo cytotoxicity to MPL positive acute myelogenous leukemia and hematopoietic stem cells.
  Jaquelyn T. Zoine, Chengyu Prince, Jamie Y. Story, Branella Gianna, Allison M Lytle, Andrew Fedanov, Jordan S. Alexander, Christopher C. Porter, Christopher B. Doering...> ;Gene Therapy. 2021 Aug 13
• 8 citations
  The RADx Tech Test Verification Core and the ACME POCT in the Evaluation of COVID-19 Testing Devices: A Model for Progress and Change
  Eric J. Nehl, Stacy Heilman, David N. Ku, David S. Gottfried, Sarah Farmer, Robert G. Mannino, Erika A. Tyburski, Julie Sullivan, Allison Suessmith, Leda Bassit, Janet...> ;IEEE Open Journal of Engineering in Medicine and Biology. 2021 Apr 28
• 2 citations
  Germline mutations: many roles in leukemogenesis.
  Kevin Z Chen, Rafi Kazi, Christopher C. Porter, Cheng Kui Qu> ;Current Opinion in Hematology. 2020 Jul 1
• 10 citations
  Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy
  Biaggio Uricoli, Lacey A Birnbaum, Priscilla Do, James M Kelvin, Juhi Jain, Emma Costanza, Andrew Chyong, Christopher C. Porter, Sarwish Rafiq, Erik C. Dreaden> ;Advanced Healthcare Materials. 2021 Mar 9
• 11 citations
  Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds.
  Jamie A.G. Hamilton, Miyoung Lee, Rae Hunter, Raira S. Ank, Jamie Y. Story, Ganesh R. Talekar, Talia Sisroe, Dov B. Ballak, Andrew Fedanov, Christopher C. Porter, Elan...> ;Aging Cell. 2021 Jan 22
• 3 citations
  Cancer Predisposition in Neonates and Infants: Recognition, Tumor Types, and Surveillance.
  Sarah Mitchell, Bojana Pencheva, Ellie Westfall, Christopher C. Porter> ;Clinics in Perinatology. 2021 Mar 1
• 2 citations
  Cancer genetic counseling for childhood cancer predisposition is associated with improved levels of knowledge and high satisfaction in parents.
  Olivia A Juarez, Bojana Pencheva, Cecelia Bellcross, Kami Wolfe Schneider, Joyce Turner, Christopher C. Porter> ;Journal of Genetic Counseling. 2021 Jun 1
• Impact of catheter size on pain and continence following robotic prostatectomy.
  Andrew W. Stamm, Basil Ferenczi, Christopher R. Porter, Paul M. Kozlowski, Ryan Donahue, John M. Corman> ;The Canadian Journal of Urology. 2020 Oct 1
• 11 citations
  ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes
  Marlie H. Fisher, Gregory Kirkpatrick, Brett M. Stevens, Courtney L. Jones, Michael U. Callaghan, Madhvi Rajpurkar, Joy M. Fulbright, Megan A. Cooper, Jesse W. Rowley,...> ;JCI Insight. 2020 Sep 17
• 7 citations
  Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia
  Priscilla Do, Lacey A Perdue, Andrew Chyong, Rae Hunter, Jodi Dougan, Curtis J. Henry, Christopher C. Porter, Erik C. Dreaden> ;ACS Combinatorial Science. 2020 Aug 3
• 5 citations
  Optical Control of Cytokine Signaling via Bioinspired, Polymer-Induced Latency.
  Lacey A Perdue, Priscilla Do, Camille David, Andrew Chyong, Anna V. Kellner, Amanda Ruggieri, Hye Ryong Kim, Khalid Salaita, Gregory B. Lesinski, Christopher C. Porter...> ;Biomacromolecules. 2020 May 29
• 12 citations
  Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia.
  Tamara B. Garcia, Rizvan C Uluisik, Annemie A. Van Linden, Kenneth L. Jones, Sujatha Venkataraman, Rajeev Vibhakar, Christopher C. Porter> ;Frontiers in Oncology. 2020 Mar 5
• 68 citations
  Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down Syndrome
  Katherine A. Waugh, Paula Araya, Ahwan Pandey, Kimberly R. Jordan, Keith P Smith, Ross E Granrath, Santosh Khanal, Eric T. Butcher, Belinda Enriquez Estrada, Angela L....> ;Cell Reports. 2019 Nov 12
• 77 citations
  ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants
  Xi Luo, Simone Feurstein, Shruthi Mohan, Christopher C. Porter, Sarah A. Jackson, Sioban Keel, Michael C. Chicka, Anna L. Brown, Chimene Kesserwan, Anupriya Agarwal, M...> ;Blood Advances. 2019 Oct 22
• 38 citations
  ETV6-related thrombocytopenia and leukemia predisposition
  Jorge Di Paola, Christopher C. Porter> ;Blood. 2019 Aug 22
• 9 citations
  Germline Genetics and Childhood Cancer: Emerging Cancer Predisposition Syndromes and Psychosocial Impacts.
  Sarah Mitchell, Bojana Pencheva, Christopher C. Porter> ;Current Oncology Reports. 2019 Aug 15
• 5 citations
  IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression.
  Jennifer L. Rabe, Lori A. Gardner, Rae Hunter, Jairo Andres Fonseca, Jodi Dougan, Christy M. Gearheart, Michael S. Leibowitz, Cathy Lee-Miller, Dmitry Baturin, Susan F...> ;Cancer Research. 2019 Jul 15
• 18 citations
  Stopping Leukemia in Its Tracks: Should Preemptive Hematopoietic Stem-Cell Transplantation be Offered to Patients at Increased Genetic Risk for Acute Myeloid Leukemia?
  Kayla V. Hamilton, Luke Maese, Jonathan M. Marron, Michael A. Pulsipher, Christopher C. Porter, Kim E. Nichols> ;Journal of Clinical Oncology. 2019 Jun 6
• 10 citations
  Macrocytic anemia in Lesch-Nyhan disease and its variants.
  Hasan Fatih Çakmaklı, Rosa J. Torres, Araceli Menendez, Gul Yalcin-Cakmakli, Christopher C. Porter, Juan G. Puig, Hyder A. Jinnah> ;Genetics in Medicine. 2019 Feb 1
• 3 citations
  Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations
  Matthew R. Hart, Donovan J. Anderson, Christopher C. Porter, Tobias Neff, Michael Levin, Marshall S. Horwitz> ;Plos Genetics. 2018 Sep 14
• 4 citations
  The genetic risk of second cancers: should the therapy for acute lymphoblastic leukemia be individualized according to germline genetic makeup?
  Kathleen Felton, Christopher C. Porter, Jun J Yang> ;Expert Review of Precision Medicine and Drug Development. 2018 Sep 3
• 12 citations
  Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine
  Tamara B. Garcia, Susan Fosmire, Christopher C. Porter> ;Leukemia Research. 2018 Jan 1
• Join now to see all

Journal Articles

• Irradiation selects for p53 mutation in hematopoietic progenitors  
  Marusyk A, Porter CC, Zaberezhnyy V, DeGregori J, PLoS Biology, 1/1/2010
• Bcl-6 over-expression correlates with monomorphic histology in children with post-transplantation lymphoproliferative disease  
  Porter CC, Liang X, Gralla J, McGavran L, Albano EA, J Pediatr Hematol/Oncol, 1/1/2008

Books/Book Chapters

• Current Pediatric Diagnosis and Treatment. 
  Chapter: Neoplastic Diseases. 
  Albano EA, Basal M, Porter CC, Foreman NK, Stork LEditors: Hay WW, Levin MJ, Sondheimer JM and RR Deterding.Appleton and Lange, New York, NYEdition 17th,2005

Abstracts/Posters

• Germline Mutations in ETV6 are Associated with In Vivo cytoplasmic Localization of ETV6 and Cause Transcriptional Dysregulation of Interferon Response Genes
  Christopher C. Porter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Combined inhibition of WEE1 and PARP1/2 synergistically inhibits acute leukemia cells by enhancing DNA damage and inducing apoptosis in vitro and in vivo.
  Garcia TB, Snedeker, JC, Porter CC, American Association for Cancer Research Annual Meeting, 1/1/2016
• ETV6 represses PAX5 expression in early B cell development.
  Jones CL, Fleenor CJ, Welsh S, Noetzli L, Fosmire S, Baturin D, Di Paola J, Hagman JR, Porter CC, American Association for Cancer Research Annual Meeting, 1/1/2016
• IFN-? Alters the Expression of Diverse Immunity Related Genes in a Cell Culture Model of Maturing Bone Marrow Neutrophils.
  Ellison MA, Gearheart CM, Porter CC and Ambruso DR, American Society of Hematology Annual Meeting, 1/1/2016
• ETV6 represses Pax5 in early B cell development.
  Jones CL, Kirkpatrick G, Fleenor CJ, Welsh S, Noetzli L, Fosmire S, Baturin D, Rowley J, Di Paola J, Hagman JR, Porter CC, American Society of Hematology Annual Meeting, 1/1/2016
• IFN-y Alters the Expression of Diverse Immunity Related Genes in a Cell Culture Model of Maturing Bone Marrow Neutrophils.
  Ellison MA, Gearheart CM, Porter CC and Ambruso DR, Blood, 1/1/2016
• ETV6 represses Pax5 in early B cell development.
  Jones CL, Kirkpatrick G, Fleenor CJ, Welsh S, Noetzli L, Fosmire S, Baturin D, Rowley J, Di Paola J, Hagman JR, Porter CC, Blood, 1/1/2016
• A dominant negative mutation (p.P214L) in ETV6 is associated with megakaryocyte and erythroid transcript misregulation.
  Noetzli L, Rowley JW, Callaghan MU, Rajpurkar M, Lee-Sherick AB, Porter CC, Weyrich AS, Di Paola JA, Blood, 1/1/2015
• Inhibition of leukemia-cell calcineurin promotes T cell-mediated suppression of leukemogenesis.
  Gardner L, Lee-Miller CA, Rabe J, Leibowitz M, Gearheart C, Patel A, Slansky J, Porter CC, Pediatr Blood Cancer; American Society of Pediatric HematologyOncology Annual Meeting, 1/1/2015
• Leukemia-cell calcineurin mediates immune evasion independent of clinically relevant modulators of the immune response.
  Patel A, Gardner L, Porter CC, Student Cancer Research Fellowship Program Poster Session, University of Colorado Cancer Center, 1/1/2014
• PTP4A3 is oncogenic and modulates triple negative breast cancer growth.
  Gari HH, Ray R, Lucia S, Porter CC, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Ru Y, Thor AD, Lambert JR, American Association for Cancer Research Annual Meeting, 1/1/2014
• MAPK signaling cascades mediate distinct prednisolone resistance mechanisms in pediatric pre-B ALL.
  Jones CL, Gearheart CM, Fosmire S, Delgado-Martin, C, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Raetz EA, Hermiston ML, Garabedian M..., American Society of Hematology Annual Meeting, 1/1/2014
• Combined inhibition of Wee1 and PARP1/2 synergistically inhibits AML cells by enhancing DNA damage and the induction of apoptosis.
  Snedeker J, Burleson T, Tibes R, Porter CC, American Society of Hematology Annual Meeting, 1/1/2014
• MAPK signaling cascades mediate distinct prednisolone resistance mechanisms in pediatric pre-B ALL.
  Jones CL, Gearheart CM, Fosmire S, Delgado-Martin, C, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Raetz EA, Hermiston ML, Garabedian M..., Blood, 1/1/2014
• Combined inhibition of Wee1 and PARP1/2 synergistically inhibits AML cells by enhancing DNA damage and the induction of apoptosis.
  Snedeker J, Burleson T, Tibes R, Porter CC, Blood, 1/1/2014
• Wee 1 as a therapeutic target in acute leukemia.
  Ford J, Baturin A, Van Linden A, Fosmire S, Porter CC, Pediatric Blood and Cancer, 1/1/2014
• Wee 1 as a therapeutic target in acute leukemia.
  Ford J, Baturin A, Van Linden A, Fosmire S, Porter CC, Department of Pediatrics, Spring Poster Session, Children's Hospital Colorado/ University of Colorado School of Medicine, 1/1/2013
• Deciphering an autophagy-dependent gene expression signature indicative of longterm prognosis for pediatric ependymoma patients.
  Gearheart CM, Birks D, Donson A, Tan AC, Forman N, Porter CC, Mulcahy-Levy J, Postdoctoral Research Poster Session, University of Colorado Denver, 1/1/2013
• Functional genomic screening to identify novel therapeutic targets in IKZF1 mutated ALL.
  Fosmire S, Ford J, Gearheart C, Porter CC, The Future of Pediatric Oncology: From Targets to Treatments Symposium, Washington, DC, 1/1/2013
• Inhibition of Wee1 enhances the anti-leukemic effects of antimetabolites in vitro and in vivo.
  Ford J, Baturin D, Van Linden A, Fosmire S, Porter CC, Blood, 1/1/2013
• Genome-Wide shRNA Screen Implicates Mitogen Activated Protein Kinase (MAPK) Pathway in Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
  Jones CL, Gearheart CM, Fosmire S, Wang J, Bitterman DS, Bhatla T, Bourgeois, Porter CC, Carroll WL, Blood, 1/1/2013
• Inhibition of Wee1 enhances the anti-leukemic effects of antimetabolites in vitro and in vivo.
  Ford J, Baturin D, Van Linden A, Fosmire S, Porter CC, Blood; American Society of Hematology Annual Meeting, 1/1/2013
• Genome-Wide shRNA Screen Implicates Mitogen Activated Protein Kinase (MAPK) Pathway in Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
  Jones CL, Gearheart CM, Fosmire S, Wang J, Bitterman DS, Bhatla T, Bourgeois, Porter CC, Carroll WL, Blood; American Society of Hematology Annual Meeting, 1/1/2013
• Wee 1 as a therapeutic target in acute leukemia.
  Ford J, Baturin A, Van Linden A, Fosmire S, Porter CC, Pediatric Blood and Cancer; American Society of Pediatric Hematology-Oncology Annual Meeting, 1/1/2013
• Use of PRT-060318, a novel Syk inhibitor, to promote cellular differentiation in acute myeloid leukemia.
  Rinella S, Porter CC, Student Cancer Research Fellowship Program Poster Session, University of Colorado Cancer Center, 1/1/2012
• Join now to see all

Lectures

• Defining the impact of trisomy 21 on the immune cell repertoire and function. 
  Boulder, CO - 1/1/2016
• Molecular mechanisms of leukemogenesis and treatment resistance. 
  Emory University School of Public Health, Atlanta, GA - 1/1/2016
• Germline mutations associated with leukemia. 
  San Diego, CA - 1/1/2016
• Chronic myeloid leukemia 
  1/1/2016
• Introduction to hematopoietic malignancies 
  1/1/2016
• Cancer and the immune system. 
  1/1/2016
• Childhood Leukemia and Lymphoma. 
  Aurora, CO - 1/1/2015
• Development of Wee1 as a therapeutic target for leukemia. 
  Children’s Hospital Colorado, Aurora, CO - 1/1/2015
• What's old is new again: familiar proteins with novel roles in leukemogenesis. 
  Emory University, Atlanta, GA - 1/1/2015
• Flow cytometry shared resource. 
  University of Colorado Cancer Center, Aurora, CO - 1/1/2015
• Calcineurin promotes immune evasion during leukemogenesis. 
  University of Colorado Cancer Center, Aurora, CO - 1/1/2015
• Balancing Work/Life and Clinical/Research Effort. 
  University of Colorado School of Medicine, Aurora, CO - 1/1/2015
• Calcineurin drives immune evasion during leukemogenesis. 
  Vail, CO - 1/1/2015
• A dominant negative mutation (p.P214L) in ETV6 is associated with megakaryocyte and erythroid transcript misregulation. 
  1/1/2015
• Pediatric Cancer: Progress and Challenge. 
  Aurora, CO - 1/1/2014
• Leukemia-cell calcineurin mediates a potent immune evasion mechanism. 
  Aurora, CO - 1/1/2014
• RNAi screens to identify novel therapeutic strategies for leukemia: going all the way. 
  Baltimore, MD - 1/1/2014
• Developing novel therapies for childhood leukemia. 
  Children’s Hospital Colorado, Aurora, CO - 1/1/2014
• Leukemia-cell calcineurin mediated immune evasion in leukemogenesis 
  Children’s Hospital Colorado, Aurora, CO - 1/1/2014
• Development of Wee1 as a therapeutic targe in ALL. 
  Lexington, KY - 1/1/2014
• Leukemia-cell calcineurin mediates a potent immune suppressive mechanism during leukemogenesis. 
  University of Colorado Cancer Center, Aurora, CO - 1/1/2014
• Immune and cell cycle checkpoints in leukemogenesis and treatment failure. 
  University of Colorado Denver, Aurora, CO - 1/1/2014
• Identification of molecular vulnerabilities in pre-B cells with Ikaros dysfunction. 
  Washington, DC - 1/1/2014
• Targeting Wee1 in pediatric leukemia 
  Boulder, CO - 1/1/2013
• Targeting Wee1 in pediatric cancer 
  Children’s Hospital Colorado, Aurora, CO - 1/1/2013
• Join now to see all

Other

• Germline mutations associated with leukemias. (Invited Review) 
  Porter CC, Hematology, American Society of Hematology Education Program
  1/1/2016
• Back to the Bedside. 
  Porter CC, ASH News Daily
  1/7/2010
• The promise of gene therapy that WAS is now. 
  CC Porter, ASH News Daily
  1/6/2010
• Inside information: insight on health-care reform from a White House advisor. 
  Porter CC, ASH News Daily
  1/6/2010
• Big Hematology: Large-scale collaborations asking genome-scale questions. 
  Porter CC, ASH News Daily
  1/5/2010
• Leukemia Stem Cells: Answers and More Questions. 
  Porter CC, ASH News Daily
  1/5/2010
• Join now to see all